1 active not recruiting, 1 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine, Rituximab, Gemcitabine - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | ADC Therapeutics S.A. | 440 | 2020-09-16 | 2026-04-28 |
| BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | City of Hope Medical Center | 3 | 2015-01-01 | 2018-03-12 |
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma (2) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma (1)
Rituximab (3) · Etoposide (2) · Carboplatin (1) · Carmustine (1) · Cytarabine (1) · Gemcitabine (1) · Ifosfamide (1) · Melphalan (1) · Oxaliplatin (1) · ibritumomab tiuxetan (1) · loncastuximab tesirine (1) · polatuzumab vedotin (1)
ADC Therapeutics S.A. (1) · City of Hope Medical Center (1) · GWT-TUD GmbH (1)
Spain (2) · United Kingdom (2) · United States (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1)